vs
Side-by-side financial comparison of PLUS THERAPEUTICS, INC. (PSTV) and SOCIETY PASS INCORPORATED. (SOPA). Click either name above to swap in a different company.
SOCIETY PASS INCORPORATED. is the larger business by last-quarter revenue ($1.4M vs $1.4M, roughly 1.0× PLUS THERAPEUTICS, INC.). SOCIETY PASS INCORPORATED. runs the higher net margin — -370.8% vs -417.9%, a 47.1% gap on every dollar of revenue. On growth, PLUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (-3.2% vs -17.6%). PLUS THERAPEUTICS, INC. produced more free cash flow last quarter ($-6.3M vs $-16.7M). Over the past eight quarters, PLUS THERAPEUTICS, INC.'s revenue compounded faster (-9.7% CAGR vs -11.2%).
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
The Wilderness Society is an Australian, community-based, not-for-profit non-governmental environmental advocacy organisation.
PSTV vs SOPA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $1.4M |
| Net Profit | $-5.7M | $-5.1M |
| Gross Margin | — | 64.3% |
| Operating Margin | -420.0% | -379.9% |
| Net Margin | -417.9% | -370.8% |
| Revenue YoY | -3.2% | -17.6% |
| Net Profit YoY | -46.4% | -271.5% |
| EPS (diluted) | $0.95 | $-0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4M | — | ||
| Q3 25 | $1.4M | $1.4M | ||
| Q2 25 | $1.4M | $2.5M | ||
| Q1 25 | $1.1M | $1.5M | ||
| Q4 24 | $1.4M | $1.9M | ||
| Q3 24 | $1.5M | $1.7M | ||
| Q2 24 | $1.3M | $1.7M | ||
| Q1 24 | $1.7M | $1.8M |
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $-4.4M | $-5.1M | ||
| Q2 25 | $5.2M | $479.0K | ||
| Q1 25 | $-17.4M | $-1.8M | ||
| Q4 24 | $-3.9M | $-4.1M | ||
| Q3 24 | $-2.9M | $-1.4M | ||
| Q2 24 | $-2.9M | $-1.9M | ||
| Q1 24 | $-3.3M | $-2.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 64.3% | ||
| Q2 25 | — | 56.5% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 26.7% |
| Q4 25 | -420.0% | — | ||
| Q3 25 | -320.8% | -379.9% | ||
| Q2 25 | -110.6% | -6.1% | ||
| Q1 25 | -333.9% | -126.6% | ||
| Q4 24 | -276.2% | -165.6% | ||
| Q3 24 | -260.9% | -70.1% | ||
| Q2 24 | -289.1% | -126.0% | ||
| Q1 24 | -196.7% | -156.6% |
| Q4 25 | -417.9% | — | ||
| Q3 25 | -316.6% | -370.8% | ||
| Q2 25 | 370.6% | 19.1% | ||
| Q1 25 | -1643.2% | -124.9% | ||
| Q4 24 | -276.4% | -217.5% | ||
| Q3 24 | -197.4% | -82.2% | ||
| Q2 24 | -229.9% | -113.3% | ||
| Q1 24 | -194.5% | -153.8% |
| Q4 25 | $0.95 | — | ||
| Q3 25 | $-0.04 | $-0.89 | ||
| Q2 25 | $-0.01 | $0.10 | ||
| Q1 25 | $-1.19 | $-0.44 | ||
| Q4 24 | $-0.51 | $-1.03 | ||
| Q3 24 | $-0.37 | $-0.48 | ||
| Q2 24 | $-0.71 | $-0.73 | ||
| Q1 24 | $-0.75 | $-1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.6M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.0M | $13.9M |
| Total Assets | $16.3M | $32.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | — | ||
| Q3 25 | $16.6M | $6.6M | ||
| Q2 25 | $6.9M | $8.2M | ||
| Q1 25 | $9.9M | $7.1M | ||
| Q4 24 | $3.6M | $7.6M | ||
| Q3 24 | $4.8M | $4.2M | ||
| Q2 24 | $8.4M | $833.9K | ||
| Q1 24 | $3.2M | $1.6M |
| Q4 25 | $4.0M | — | ||
| Q3 25 | $5.1M | $13.9M | ||
| Q2 25 | $3.0M | $2.4M | ||
| Q1 25 | $-23.6M | $-663.0K | ||
| Q4 24 | $-8.9M | $-2.1M | ||
| Q3 24 | $-5.2M | $862.6K | ||
| Q2 24 | $-7.6M | $2.4M | ||
| Q1 24 | $-4.8M | $3.5M |
| Q4 25 | $16.3M | — | ||
| Q3 25 | $18.7M | $32.9M | ||
| Q2 25 | $10.3M | $29.2M | ||
| Q1 25 | $12.1M | $22.9M | ||
| Q4 24 | $6.6M | $21.3M | ||
| Q3 24 | $7.0M | $17.0M | ||
| Q2 24 | $11.2M | $13.0M | ||
| Q1 24 | $5.6M | $13.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-16.7M |
| Free Cash FlowOCF − Capex | $-6.3M | $-16.7M |
| FCF MarginFCF / Revenue | -459.9% | -1211.0% |
| Capex IntensityCapex / Revenue | 2.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-20.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-2.5M | $-16.7M | ||
| Q2 25 | $-5.8M | $-1.8M | ||
| Q1 25 | $-6.2M | $-4.0M | ||
| Q4 24 | $-1.2M | $3.7M | ||
| Q3 24 | $-3.7M | $2.0M | ||
| Q2 24 | $-1.1M | $-864.6K | ||
| Q1 24 | $-4.5M | $-2.4M |
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-2.6M | $-16.7M | ||
| Q2 25 | $-5.8M | — | ||
| Q1 25 | $-6.2M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | -459.9% | — | ||
| Q3 25 | -184.3% | -1211.0% | ||
| Q2 25 | -417.6% | — | ||
| Q1 25 | -583.1% | — | ||
| Q4 24 | -86.5% | — | ||
| Q3 24 | -253.7% | — | ||
| Q2 24 | -96.2% | — | ||
| Q1 24 | -271.5% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.9% | 0.0% | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.13× | -3.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
